STOCK TITAN

Tyra Biosciences (TYRA) Stock Price, News & Analysis

TYRA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
39 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+26.4% close of November 20, 2025
1-year change
+25.5% closing prices, November 14, 2025 to November 16, 2026
1-month change
+6.6% closing prices, October 16, 2026 to November 16, 2026

Company Description

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company operating in the research and development segment of biotechnology within the professional, scientific, and technical services sector. According to its public disclosures, Tyra Biosciences focuses on developing next-generation precision medicines that target opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, with an emphasis on genetically defined conditions and targeted oncology. The company is based in Carlsbad, California and its common stock trades on the Nasdaq Global Select Market under the symbol TYRA.

Tyra Biosciences has built its pipeline around an in-house precision medicine discovery engine called SNÅP. The company states that SNÅP enables rapid and precise drug design through iterative molecular “SNÅPshots” that help predict genetic alterations most likely to cause acquired resistance to existing therapies. This platform is used to design oral, small-molecule FGFR inhibitors with specific selectivity profiles intended to address FGFR-driven diseases.

Focus on FGFR Biology and Precision Medicines

Across its communications, Tyra Biosciences describes a focused expertise in FGFR biology. The company reports that this focus has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its programs are centered on inhibiting different FGFR family members (FGFR1, FGFR2, FGFR3 and FGFR4) in ways that are intended to match the underlying genetic drivers of disease.

The company highlights that its lead precision medicine candidates are designed as oral, investigational FGFR-selective inhibitors. These candidates are being evaluated in conditions where FGFR pathway alterations are known to play a role, including skeletal dysplasias and specific cancers such as non-muscle invasive bladder cancer, metastatic urothelial carcinoma, intrahepatic cholangiocarcinoma and hepatocellular carcinoma, as described in Tyra’s press releases and SEC filings.

Key Pipeline Programs

Tyra Biosciences’ disclosures describe three main clinical-stage product candidates stemming from the SNÅP platform:

  • Dabogratinib (formerly TYRA-300): Tyra describes dabogratinib as its lead precision medicine candidate and a potential first-in-class, oral, FGFR3-selective inhibitor. It is being developed for the treatment of skeletal dysplasia and urologic cancers. The company reports that dabogratinib has demonstrated interim clinical proof-of-concept results in metastatic urothelial carcinoma (mUC) and is being evaluated in multiple planned or ongoing Phase 2 studies, including:
    • BEACH301 – a Phase 2, multicenter, open-label, dose-escalation/dose-expansion study in children with pediatric achondroplasia, a form of skeletal dysplasia.
    • SURF302 – a Phase 2, open-label clinical study in participants with FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
    • SURF303 – a planned Phase 2 study in low-grade upper tract urothelial carcinoma (LG-UTUC), where Tyra notes that FGFR3 alterations occur in a high proportion of cases.
    • SURF301 – a Phase 1/2 study in metastatic urothelial carcinoma (mUC), where dabogratinib continues to be evaluated at once-daily doses.
  • TYRA-430: Tyra describes TYRA-430 as an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. It is being studied in SURF431, a Phase 1, multicenter, open-label, first-in-human study enrolling adults with advanced hepatocellular carcinoma (HCC) and other solid tumors with activating FGF/FGFR pathway aberrations.
  • TYRA-200: TYRA-200 is described as an oral, investigational FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations. It is being evaluated in SURF201, a Phase 1, multi-center, open-label study in adults with unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating FGFR2 alterations.

Clinical-Stage Development Areas

Based on company press releases and SEC filings, Tyra Biosciences is concentrating its clinical development on two broad areas:

  • Genetically defined skeletal dysplasias: The company is developing dabogratinib for achondroplasia, which it describes as the most common form of dwarfism and a skeletal dysplasia caused by an alteration in FGFR3. Tyra notes that dabogratinib is an oral FGFR3-selective inhibitor designed to target the root cause of achondroplasia and that it is the only oral FGFR3-selective inhibitor in clinical development for this condition according to its communications.
  • FGFR-driven cancers: Tyra’s programs include clinical studies in non-muscle invasive bladder cancer, metastatic urothelial carcinoma, intrahepatic cholangiocarcinoma and hepatocellular carcinoma, all in settings where FGFR pathway alterations are relevant. The company emphasizes the use of FGFR-selective inhibitors to match these molecular drivers.

Regulatory Designations and Trial Design Features

Tyra Biosciences reports that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia. The company describes multiple ongoing or planned multicenter, open-label Phase 1 and Phase 2 studies, with endpoints such as safety, tolerability, complete response rate, time to recurrence, duration of response, and progression-free survival, as detailed in its press releases and the related Form 8-K filings.

The company’s disclosures also highlight that its clinical trials enroll participants at sites across different regions, including global enrollment for the BEACH301 pediatric achondroplasia study and multiple sites primarily in the United States for the SURF302 IR NMIBC study.

Business Model and Stage

From the available information, Tyra Biosciences is described as a clinical-stage company. Its activities, as reported in press releases and SEC filings, are focused on research and development, clinical trial execution, and regulatory strategy for its investigational drug candidates. The company’s reported financial results emphasize research and development expenses, general and administrative expenses, and net loss, consistent with an early-stage biotechnology business that is investing in clinical programs rather than commercial operations.

Stock Information

According to Tyra’s Form 8-K filed on June 30, 2025, the company’s common stock, par value $0.0001 per share, is registered on the Nasdaq Global Select Market under the trading symbol TYRA. The filings and press releases do not indicate any delisting, deregistration, merger completion, or bankruptcy events, and instead reference ongoing clinical and corporate activities.

Summary

In summary, Tyra Biosciences, Inc. is a Carlsbad, California-based, clinical-stage biotechnology company listed on Nasdaq under the symbol TYRA. It focuses on precision medicines in FGFR biology, built on its SNÅP platform, and has a pipeline of oral FGFR-targeted small molecules in clinical development for achondroplasia, non-muscle invasive bladder cancer, metastatic urothelial carcinoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven conditions, as described in its public communications.

Stock Performance

$19.74
-1.42%
-0.29
Last updated: November 16, 2026 at 16:00
+25.5%
Performance 1 year

Tyra Biosciences (TYRA) closed at $19.74 on November 16, 2026. Over the past 12 months, the price has gained 25.5%.

See what a $1,000 investment in TYRA would be worth today

Average down calculator for TYRA

TYRA Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Tyra Biosciences has 10 recent news articles, with the latest published 6 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, conferences, offering, clinical trial. View all TYRA news →

Insider Radar

Net Buyers
90-Day Summary
Security Bought Sold
Warrants 9,078,529 $199,990,915 0
Common shares 972 $20,000 0
2
Transactions
Most Recent Transaction
RA Capital Healthcare Fund LP (Director) bought 9,078,529 warrants held indirectly @ $22.03 on September 15, 2026

Insider buying activity at Tyra Biosciences over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Tyra Biosciences reported operating income of -$132.8M in FY2025, and net income was -$119.9M. Diluted earnings per share stood at -$2.01. The company generated -$95.1M in operating cash flow. The current ratio was 14.67, measuring current assets divided by current liabilities.

-$119.9M
Net Income (FY2025)
-$95.1M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
16
November 16, 2026 Marketing

Jefferies presentation

Hybrid presentation at Jefferies London conference on 2026-11-16 at 11:30 AM GMT; live webcast and replay via Tyra investor website.
Q1
2027
Q1 2027 Clinical

BEACH301 safety sentinel

Safety-sentinel data readout for BEACH301 Phase 2 achondroplasia study expected by end of Q1 2027; Tyra to announce timing.
YEAR
2027
2027 Clinical

Phase 3 initiation

Tyra expects to initiate Phase 3 dabogratinib program in 2027, timing subject to regulatory feedback and review.
YEAR
2027
2027 Clinical

Bladder cancer results

Tyra expects additional bladder-cancer and upper-tract dabogratinib results during 2027; readouts may affect development plans.
YEAR
2027
2027 Clinical

Achondroplasia results

Initial achondroplasia results from BEACH301 and related studies are expected in 2027; could inform dosing and enrollment.

Tyra Biosciences has 5 upcoming scheduled events. The next event, "Jefferies presentation", is scheduled for November 16, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the TYRA stock price.

Short Interest History

Last 12 Months

Short interest in Tyra Biosciences (TYRA) currently stands at 9.9 million shares, up 4.3% from the previous reporting period, representing 14.8% of the float. Since November 2025, short interest has increased by 138.8%.

Days to Cover History

Last 12 Months

Days to cover for Tyra Biosciences (TYRA) currently stands at 15.3 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 165.7%. Across the settlements charted above, it has ranged from 4.1 to 27.1 days.

TYRA Company Profile & Sector Positioning

Tyra Biosciences (TYRA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing TYRA often look at related companies in the same sector, including Structure Therapeutics Inc. (GPCR), Ascentage Pharma Group International (AAPG), Intellia Therapeutics, Inc (NTLA), Mineralys Therapeutics, Inc. (MLYS), and Absci Corporation (ABSI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TYRA's relative position within its industry.

Frequently Asked Questions

The current stock price of Tyra Biosciences (TYRA) is $19.74 as of November 16, 2026.

The market cap of Tyra Biosciences (TYRA) is approximately $1.4B. Learn more about what market capitalization means .

The FY2025 net income of Tyra Biosciences (TYRA) is -$119.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Tyra Biosciences (TYRA) is -$2.01 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Tyra Biosciences (TYRA) is -$95.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Tyra Biosciences (TYRA), current assets divided by current liabilities, was 14.67 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Tyra Biosciences (TYRA) is -$132.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company that focuses on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. According to its public disclosures, the company uses its in-house SNÅP platform to design oral FGFR-selective inhibitors for genetically defined conditions and targeted oncology indications.

Tyra Biosciences describes SNÅP as its in-house precision medicine discovery engine. The platform enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. This approach is used to develop the company’s FGFR-targeted small-molecule drug candidates.

Based on company communications, Tyra Biosciences focuses on targeted oncology and genetically defined conditions. Its clinical-stage programs include indications such as intermediate risk non-muscle invasive bladder cancer, metastatic urothelial carcinoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma and skeletal dysplasias such as achondroplasia, where FGFR pathway alterations play a key role.

Dabogratinib, previously referred to as TYRA-300, is Tyra Biosciences’ lead precision medicine candidate. The company describes it as an investigational, oral, FGFR3-selective inhibitor being developed for skeletal dysplasia and urologic cancers. Dabogratinib has shown interim clinical proof-of-concept results in metastatic urothelial carcinoma and is being evaluated in Phase 2 studies such as BEACH301 for pediatric achondroplasia and SURF302 for FGFR3-altered intermediate risk non-muscle invasive bladder cancer.

TYRA-200 is described by the company as an oral, investigational FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations. It is being studied in the SURF201 Phase 1 trial in intrahepatic cholangiocarcinoma and other FGFR2-altered tumors. TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, evaluated in the SURF431 Phase 1 study in advanced hepatocellular carcinoma and other solid tumors with FGF/FGFR pathway aberrations.

Tyra Biosciences is developing dabogratinib for pediatric achondroplasia, which it describes as the most common form of dwarfism caused by an alteration in FGFR3. The company has initiated BEACH301, a Phase 2, multicenter, open-label, dose-escalation/dose-expansion study in children ages 3 to 10 with achondroplasia who have open growth plates. Tyra notes that dabogratinib is an oral FGFR3-selective inhibitor and that the FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in this indication.

According to Tyra Biosciences’ Form 8-K filed on June 30, 2025, the company’s common stock, par value $0.0001 per share, is registered on the Nasdaq Global Select Market under the trading symbol TYRA.

Tyra Biosciences states in its press releases that it is based in Carlsbad, California. This location is consistently referenced in the company’s news announcements and corporate descriptions.

The company reports that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to dabogratinib for the treatment of achondroplasia. These designations are mentioned in Tyra’s press releases describing the BEACH301 study and its achondroplasia program.

Tyra Biosciences repeatedly describes itself as a clinical-stage biotechnology company in its press releases and investor communications. Its reported activities focus on research and development, clinical trials and regulatory interactions for its investigational drug candidates, rather than on marketed products.